中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2010年
11期
1648-1650
,共3页
强廷会%王栓科%康学文%夏亚一%汪静%李鹏
彊廷會%王栓科%康學文%夏亞一%汪靜%李鵬
강정회%왕전과%강학문%하아일%왕정%리붕
骨肉瘤%环氧合酶抑制剂%CD44%金属蛋白酶
骨肉瘤%環氧閤酶抑製劑%CD44%金屬蛋白酶
골육류%배양합매억제제%CD44%금속단백매
Osteosarcoma%Inhibitor of COX-2%CD44%Metalloproteinase
目的 观察环氧合酶2(COX-2)抑制剂塞来昔布对骨肉瘤MG-63和U2-OS细胞增殖、黏附和侵袭的抑制作用,探讨其分子机制.方法 采用噻唑蓝(MTF)比色法、黏附实验、侵袭实验、流式细胞术和Western blot研究25、50、100 μmol/L 3种浓度塞来昔布对两种细胞株增殖、黏附、侵袭能力及CD44和基质金属酶(MMP)-9表达的影响.结果 3种浓度的塞来昔布作用48 h后MG-63细胞增殖抑制率分别为9.35%、42.68%、60.29%(P＜0.05),对U2-OS细胞的抑制率分别为2.59%、8.95%、29.36%(P＜0.05).对MG-63的黏附抑制率分别为8.6%、21. 5%、52.8%(P＜0.05);对U2-OS的黏附抑制率分别为1.6%、3.8%、19.0%(P＜0.05);对两种骨肉瘤细胞的侵袭能力、CD44和MMP-9的表达均有抑制作用,对高表达COX-2的MG-63的抑制效应更加显著.结论 塞来昔布可抑制骨肉瘤细胞的增殖、黏附和侵袭,这种作用与下调CD44和MMP-9的表达有关,此种效应具有COX-2依耐性.
目的 觀察環氧閤酶2(COX-2)抑製劑塞來昔佈對骨肉瘤MG-63和U2-OS細胞增殖、黏附和侵襲的抑製作用,探討其分子機製.方法 採用噻唑藍(MTF)比色法、黏附實驗、侵襲實驗、流式細胞術和Western blot研究25、50、100 μmol/L 3種濃度塞來昔佈對兩種細胞株增殖、黏附、侵襲能力及CD44和基質金屬酶(MMP)-9錶達的影響.結果 3種濃度的塞來昔佈作用48 h後MG-63細胞增殖抑製率分彆為9.35%、42.68%、60.29%(P＜0.05),對U2-OS細胞的抑製率分彆為2.59%、8.95%、29.36%(P＜0.05).對MG-63的黏附抑製率分彆為8.6%、21. 5%、52.8%(P＜0.05);對U2-OS的黏附抑製率分彆為1.6%、3.8%、19.0%(P＜0.05);對兩種骨肉瘤細胞的侵襲能力、CD44和MMP-9的錶達均有抑製作用,對高錶達COX-2的MG-63的抑製效應更加顯著.結論 塞來昔佈可抑製骨肉瘤細胞的增殖、黏附和侵襲,這種作用與下調CD44和MMP-9的錶達有關,此種效應具有COX-2依耐性.
목적 관찰배양합매2(COX-2)억제제새래석포대골육류MG-63화U2-OS세포증식、점부화침습적억제작용,탐토기분자궤제.방법 채용새서람(MTF)비색법、점부실험、침습실험、류식세포술화Western blot연구25、50、100 μmol/L 3충농도새래석포대량충세포주증식、점부、침습능력급CD44화기질금속매(MMP)-9표체적영향.결과 3충농도적새래석포작용48 h후MG-63세포증식억제솔분별위9.35%、42.68%、60.29%(P＜0.05),대U2-OS세포적억제솔분별위2.59%、8.95%、29.36%(P＜0.05).대MG-63적점부억제솔분별위8.6%、21. 5%、52.8%(P＜0.05);대U2-OS적점부억제솔분별위1.6%、3.8%、19.0%(P＜0.05);대량충골육류세포적침습능력、CD44화MMP-9적표체균유억제작용,대고표체COX-2적MG-63적억제효응경가현저.결론 새래석포가억제골육류세포적증식、점부화침습,저충작용여하조CD44화MMP-9적표체유관,차충효응구유COX-2의내성.
Objective To evaluate the effects of cyclooxygenase-2 (COX-2) inhibitor Celecoxib on the proliferation, adhesion and invasion of MG-63 and U2-OS osteosarcoma cell lines, and explore the molecular mechanisms. Methods Methyl thiazol tetrazolium (MTT) assay, adhesive assay and Transwell chamber in vitro invasion assay were employed to examine the change of the proliferation, adhesion and invasion ability of the cell lines which treated by different concentrations (25, 50, 100 μmol/L) of celecoxib for 24 h.Flow cytometry and Western blotting were used to detect the change of CD44 and matrix metalloproteinase (MMP)-9 expression after the treatment. Results The proliferation inhibition rate of the three concentrations of celecoxib on MG-63 cell line was 9. 35%, 42. 68%, 60. 29% (P ＜0. 05) respectively, on U2-0S cell line was 2. 59%, 8. 95%, 29. 36% (P ＜0. 05) respectively; the adhesive inhibition rate on MG-63 cell line was 8.6%, 21.5%, 52.8% (P＜0.05) respectively, on U2-OS was 1.6%, 3.8%, 19.0% (P＜0. 05) respectively. The invasion ability and the expression of CD44 and MMP-9 in MG-63 and U2-OS cells were inhibited by celecoxib, but the inhibition effect was more obvious in MG-63 which expressed higher COX-2. Conclusion The selective COX-2 inhibitor celecoxib can inhibit the proliferation, adhesion and invasion of human osteosarcoma cell lines through downregulating the level of CD44 and MMP-9, which was COX-2-dependent.
